Methyldopa and Celebrex drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Methyldopa (methyldopa) and Celebrex (celecoxib). Common drug interactions include dyspnoea among females and cerebrovascular accident among males.

The phase IV clinical study analyzes what interactions people have when they take Methyldopa and Celebrex. It is created by eHealthMe based on reports of 44 people who take the same drugs from the FDA, and is updated regularly.

What is Methyldopa?

Methyldopa has active ingredients of methyldopa. It is often used in high blood pressure. eHealthMe is studying from 6,475 Methyldopa users. Check the latest studies of Methyldopa.

What is Celebrex?

Celebrex has active ingredients of celecoxib. It is often used in arthritis. eHealthMe is studying from 151,106 Celebrex users. Check the latest studies of Celebrex.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Sep, 01, 2026

44 people who take Methyldopa and Celebrex together, and have interactions are studied.

Methyldopa and Celebrex drug interactions.

What are the common drug interactions of Methyldopa and Celebrex, by gender? *:

female:

  1. Dyspnoea (difficult or laboured respiration)
  2. Extrapyramidal disorder (involuntary muscle spasms in the face and neck)
  3. Fatigue (feeling of tiredness)
  4. Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
  5. Injury
  6. Tardive dyskinesia (a disorder that involves involuntary movements)
  7. Visual impairment
  8. Arthralgia (joint pain)
  9. Chest pain
  10. Constipation

male:

  1. Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
  2. Gastrointestinal haemorrhage (bleeding gastrointestinal tract)

What are the common drug interactions of Methyldopa and Celebrex, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Abortion spontaneous (naturally occurring miscarriage)
  2. Cough
  3. Dyspnoea (difficult or laboured respiration)
  4. Fatigue (feeling of tiredness)
  5. Pneumonia
  6. Pyrexia (fever)
  7. Rash papular (redness with papule)
  8. Rash pruritic (redness with itching)

40-49:

  1. Abortion spontaneous (naturally occurring miscarriage)
  2. Maternal exposure during pregnancy (use of substance during pregnancy)
  3. Rheumatoid arthritis (a chronic progressive disease causing inflammation in the joints)
  4. Chest pain
  5. Pulmonary fibrosis (formation or development of excess fibrous connective tissue (fibrosis) in the lungs)
  6. Abdominal distension
  7. Abdominal pain
  8. Anxiety
  9. Arthralgia (joint pain)
  10. Asthenia (weakness)

50-59:

  1. Arthralgia (joint pain)
  2. Asthma
  3. Back pain
  4. Bile duct stone
  5. Blood chloride decreased
  6. Blood glucose decreased
  7. Blood glucose increased
  8. Blood immunoglobulin g increased
  9. Blood sodium decreased
  10. Blood thyroid stimulating hormone decreased

60+:

  1. Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
  2. Visual impairment
  3. Alopecia (absence of hair from areas of the body)
  4. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  5. Coronary artery disease (plaque building up along the inner walls of the arteries of the heart, which narrows the arteries and restricts blood flow to the heart)
  6. Cough
  7. Drug effect decreased
  8. Embolic stroke (stroke due to obstruction due to an embolus)
  9. Extrapyramidal disorder (involuntary muscle spasms in the face and neck)
  10. Hallucination (an experience involving the perception of something not present)

What are the existing conditions these people have? *

  1. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 6 people, 13.64%
  2. Pain: 6 people, 13.64%
  3. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 5 people, 11.36%
  4. Osteoarthritis (a joint disease caused by cartilage loss in a joint): 4 people, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Methyldopa and Celebrex?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Methyldopa and Celebrex:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Methyldopa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Celebrex:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Methyldopa and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Celebrex and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on methyldopa and celecoxib (the active ingredients of Methyldopa and Celebrex, respectively), and Methyldopa and Celebrex (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: